HSK39297

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AnemiaParoxysmal Nocturnal Hemoglobinuria

272 competitors in Anemia

#DrugCompanyPhaseTrials

1

Rituxan

Roche

Phase 3

22

Feosol

AAuerbach Hematology Oncology Associates P C

Phase 3

93

Ultomiris

AstraZeneca

Phase 3

14

Cytoxan

BBaxter Healthcare Corporation

Phase 3

65

Omontys

Takeda

Phase 3

96

Alkeran

AApotex Inc.

Phase 3

17

Jesduvroq

GGlaxo Dba Glaxosmithkline

Phase 3

28

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

529

Aranesp

Amgen

Preclinical

3810

HSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

1Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Efficacy and Safety3 trials

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

Recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT07363460·105 enrolled

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

Recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT06670352·80 enrolled

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 3·NCT07390123·370 enrolled

Paroxysmal Nocturnal Hemoglobinuria3 trials

Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT06745622·47 enrolled

A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Completed·Haisco Pharmaceutical Group Co., Ltd.·Phase 3·NCT06799546·73 enrolled

A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）

Completed·Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT06561841·47 enrolled

Hepatic Impairment1 trial

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

Recruiting·Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT07152288·24 enrolled

Anemia1 trial

Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia

Completed·Haisco Pharmaceutical Group Co., Ltd.·Phase 3·NCT07052838·36 enrolled

ESS1 trial

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

Completed·Haisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT06350279·96 enrolled

Details

Drug Info

Related News